MAPT and Alzheimer disease: To further assess blood BD-tau in non-AD cognitive impairment, we sourced additional non-AD (Aβ negative MCI) cases (n = 143) from cohort 1 along with cognitively impaired non-AD cases (MCI/Dementia) from cohort 3 (n = 35).